Friday June 23rd 2017

CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple…

Conclusions: We propose two novel biomarkers, ex vivo CD80+ B cells positively correlating to disease severity and CD86+ B cells preferentially induced by IFN-beta, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS. (Source: Epidemiologic Perspectives and Innovations)

Continued here: 

CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple…

Leave a Comment

More from category

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]

MS Society Disappointed with Senate Healthcare Bill
MS Society Disappointed with Senate Healthcare Bill

/About-the-Society/News/HealthcareBill-6-22 [Read More]

Type I interferons could have role in natural improvement of RA during pregnancy
Type I interferons could have role in natural improvement of RA during pregnancy

An international US-Danish team of scientists, led by Damini Jawaheer, Ph.D. at the UCSF Benioff Children's Hospital [Read More]

Shared decision-making essential to optimal treatment and quality of life for patients with MS
Shared decision-making essential to optimal treatment and quality of life for patients with MS

One of the cornerstones of multiple sclerosis treatment is shared decision-making between patients and their doctors [Read More]

UC consortium formed to speed up development of new drugs
UC consortium formed to speed up development of new drugs

For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the [Read More]